[Biosimilars or follow-on biologics in dermatology].
Puig
L
L
Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, España. lpuig@santpau.cat
D001688:Biological Products / Q000737:chemistry / Q000191:economics / Q000493:pharmacokinetics; D002681:China; D003879:Dermatologic Agents / Q000737:chemistry / Q000191:economics / Q000493:pharmacokinetics; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004340:Drug Contamination; D016527:Drug Costs; D005060:Europe; D007194:India; D040541:Marketing / Q000191:economics / Q000331:legislation & jurisprudence; D011994:Recombinant Proteins / Q000737:chemistry / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D013030:Spain; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products; D003879:Dermatologic Agents; D011994:Recombinant Proteins